Citations

Clear

114 citation(s) found for "Maria, Lapid".

Transcranial Electrical Stimulation in Treatment of Depression
Ren, Caili , Wang, Zhen , Kung, Simon , Boyapati, Renu Bhargavi, Islam, Karimul , Li, John Wing , Shelton, K. Maureen, Waniger, Anne , Rydberg, Ann , Pascual–Leone, A., Pagali, Sandeep R. , Li, John W, Rydberg, Ann M, Boyapati, Renu Bhargavi, Islam, Karimul, Hassett, Leslie C. , Croarkin, Paul E. , Lundstrom, Brian N. , Lapid, Maria I.

Mayo Clinic

JAMA Network Open | June 18, 2025 | Volume: 8 | Issue: 6 | Pages: e2516459

10.1001/jamanetworkopen.2025.16459 | PMID 40531534 Get It

Importance The role and safety of transcranial electrical stimulation (tES) for treating depressive disorders remain under evaluation. Objective To evaluate tES treatment in patients with major depressive disorder (MDD) and comorbid depressive conditions. Data Sources A search of MEDLINE, Embase, Cochrane, APA PsycINFO, and Scopus databases was conducted from inception to September 17, 2024. Study Selection Randomized clinical trials (RCTs) of adults with MDD, depression with psychiatric comorbidities (DPC), or depression with medical comorbidities (DMC), treated with transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS), compared with sham or other treatments were included. Data Extraction and Synthesis Independent reviewers extracted data in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, with random-effects meta-analysis used for pooling. Main Outcomes and Measures Primary outcomes were depression severity, response and remission rates, and adverse events. Standardized mean differences (SMDs) were reported for continuous outcomes, and odds ratios (ORs) were reported for categorical outcomes. Quality of evidence (QOE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation criteria. Results The meta-analysis included 5522 participants from 114 study groups from 88 RCTs (3198 female [58.9%]; mean [range] age, 43.1 [19.4-76.9] years). Most studies (104 study groups from 79 RCTs [91.2%]) evaluated tDCS, while 7 study groups from 6 RCTs (6.1%) evaluated tACS, and 3 study groups from 3 RCTs (2.7%) evaluated tRNS. tES was associated with reduced depressive symptoms (SMD = −0.59; 95% CI, −0.83 to −0.35; low QOE) and improvement in DMC (SMD = −1.05; 95% CI, −1.67 to −0.43; low QOE) and DPC (SMD = −0.78; 95% CI, −1.27 to −0.29; low QOE) compared with MDD (SMD = −0.22; 95% CI, −0.44 to 0.01; low QOE). tDCS was associated with reduced depression in DMC (SMD = −1.05; 95% CI, −1.70 to −0.40; very low QOE) and DPC (SMD = −0.88; 95% CI, −1.40 to −0.36; low QOE) but not MDD. tACS was associated with improved MDD symptoms (SMD = −0.58; 95% CI, −0.96 to −0.20; high QOE) and response rates (OR, 2.07; 95% CI, 1.34 to 3.19; high QOE). Combined tDCS and medication was associated with reduced symptoms (SMD = −0.51; 95% CI, −0.90 to −0.13; moderate QOE) and increased response (OR, 2.25; 95% CI, 1.08 to 4.65; high QOE) in MDD. tDCS combined with psychotherapy was not associated with improvement. Subgroup analysis showed that anodal left dorsolateral prefrontal cortex DCS was associated with improved outcomes. Mild to moderate adverse events were more frequent in tES groups. Conclusions and Relevance In this systematic review and meta-analysis, tDCS was associated with improvement in depression among patients with DMC and DPC (with smaller benefits in MDD), tACS was associated with improved MDD outcomes (while tRNS had insufficient evidence) in smaller samples, and combined tDCS and medication was associated with improvement in depression. These findings suggest that tES is well-tolerated overall, with only mild to moderate adverse events, and that future research should optimize stimulation parameters and individualize tES interventions.
Spouse and Child Caregivers’ Experiences of Lucid Episodes in Dementia: A Mixed Methods Approach
Kim, Kyungmin , Bangerter, Lauren R. , Liu, Yin , Finnie, Dawn M., Gaugler, Joseph E. , Griffin, Joan M. , Gaugler, Joseph E , Griffin, Joan M , Lapid, Maria I. , Kim, Kyungmin

Mayo Clinic

Innovation in Aging | June 10, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/geroni/igaf036 | PMID 40502729 Get It

Abstract Background and Objectives Lucid episodes (LEs) in people living with late-stage dementia have been reported anecdotally. However, how this seemingly unexpected phenomenon is experienced by family caregivers is less known. Focusing on the two most common groups of informal caregivers, spouses and adult children, this study examined variability in family caregivers’ experiences with LEs—whether they exhibit differential appraisals of and responses to LEs. Research Design and Methods Using a sample of former/bereaved and current family caregivers from UsAgainstAlzheimer’s A-LIST, we conducted an online survey of spouse and child caregivers (N = 387). We conducted semistructured interviews among a subset of caregivers who witnessed a LE (n = 22). Results Overall, child caregivers were more likely to witness a LE than spouse caregivers. Among former/bereaved caregivers who witnessed a LE (n = 139), spouses were likely to report nonverbal communication during LEs, appraise LEs more negatively, and make changes in care decisions, such as end-of-life planning and financial decisions, compared to adult children. Among current caregivers who witnessed a LE (n = 80), spouses often reported no special circumstances preceding LEs, whereas children linked LEs to friend/family visits. No significant differences were found in positive and negative appraisals of LEs between current spouse and child caregivers. Content analysis of qualitative interviews revealed the contexts underlying these differences. Discussion and Implications Differences between spouses and adult children in their experiences with LEs are related to their different caregiving contexts, including relationship history, living arrangements, expectations, motivations, and caregiving resources.
Three approaches to determining clinically meaningful benefit on the Cohen‐Mansfield Agitation Inventory in dementia clinical trials for agitation
Liu, Kathy , Ivenso, Chineze , Rapaport, Penny , Reeves, Suzanne , Schneider, Lon S. , Group, Agitation MCID Study, Howard, Robert, Howard, Robert , Liu, Kathy Y , Reeves, Suzanne , Howard, Rebecca, Banerjee, Sube , Lapid, Maria I. , Group, Agitation MCID Study, Howard, Robert

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 15, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70099 | PMID 40376142 Get It

Abstract INTRODUCTION There is a need to understand the clinical meaningfulness of symptom score changes in treatment trials of dementia‐related agitation. We estimated minimal clinically important differences (MCIDs) for commonly employed agitation scales and contextualized their clinical application. METHODS We employed anchor‐ and distribution‐based approaches to determine changes in scores corresponding to minimal symptom improvement. An opinion‐based approach assessed expert clinicians’ agreement on the meaningfulness of score changes through three clinical vignettes. RESULTS Minimal symptom improvement for Cohen‐Mansfield Agitation Inventory total score ranged from −4 (over <1 month) to −11 (over 1 to 3 months) points. Greater symptom severity correlated with higher MCID estimates. The clinical importance of score changes was influenced by treatment duration, pharmacological side effects, and impacts on caregiver distress/time resources. DISCUSSION The clinical meaningfulness of agitation scale MCIDs is influenced by trial‐specific and clinical factors. Shorter trial durations and measuring caregiver distress/time resources enhance the clinical interpretation of agitation treatment outcomes. Highlights For the CMAI total score, the MCID was −4 points over shorter time scales and −11 points for longer time scales. Worse agitation severity was associated with higher MCID estimates. There was high expert consensus that a noticeable treatment benefit was not worthwhile if it occurred after 12 weeks or had no impact on caregiver/staff distress/time resources.
Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Memel, Molly , Staffaroni, Adam M. , Ilan‐Gala, Ignacio, Castro, J. García , Kornak, John , Tartaglia, Carmela M., Saloner, Rowan, Cadwallader, Claire J. , Chen, Coty , Gorno‐Tempini, Maria Luisa , Mandelli, Malu, Apostolova, Liana , Graff-Radford, N. R., Pressman, Peter , Miyagawa, Toji , Mackenzie, Ian R. , Darby, R. Ryan , Petrucelli, Len, Gendron, Tania, Heuer, Hilary W. , Forseberg, Leah K., Brushaber, Nellie, Domoto‐Reilly, Kimiko , Ghoshal, Nupur , Pascual, Belén , Lee, Suzee, Ramos, Eliana Marisa , Rademakers, Rosa , Rascovsky, Katya, Masdeu, Joseph C. , Boxer, Adam L., Rosen, Howard J. , Casaletto, Kaitlin B. , Illán‐Gala, Ignacio , Graff-Radford, Neil, Boeve, Brad F, Pascual, Belen , Domoto-Reilly, Kimiko , Garcia Castro, Jesús , Illán-Gala, Ignacio , Saloner, Rowan , VandeBunte, Anna M. , Paolillo, Emily W. , Litvan, Irene , Bayram, Ece , Goldman, Jill , Appleby, Brian S. , Gendron, Tania F. , Rojas, Julio C. , Boeve, Bradley F. , Lapid, Maria I. , Ramanan, Vijay K. , Pantelyat, Alexander , Masdeu, Joseph C , Snyder, Allison , Boxer, Adam L.

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14630 | PMID 40277077 Get It

Abstract INTRODUCTION Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). METHODS Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to 6 years. Linear mixed‐effects models investigated how sex and disease stage are associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL). RESULTS While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. DISCUSSION In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD‐causing mutations. Highlights Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.
Patient Interest Is Not Enough: Additional Challenges for DBS in MCI
Tripp, Ellery R. , Ellertson, Marka F. , Lapid, Maria I. , Worrell, Gregory A. , Louis, Erik K. St. , Ellertson, Marka , St Louis, E K , Sharp, Richard R , Lapid, Maria I. , Worrell, Gregory A , Sharp, Richard R.

Mayo Clinic

AJOB Neuroscience | April 10, 2025 | Volume: 16 | Issue: 2 | Pages: 88-90

10.1080/21507740.2025.2474227 | PMID 40208679 Get It

Neuropsychiatric symptoms cluster and fluctuate over time in behavioral variant frontotemporal dementia
Morrow, Christopher B. , Eldaief, Mark C. , Rezaii, Neguine, Wong, Bonnie , McGinnis, Scott, Darby, Ryan, Staffaroni, Adam M. , Pascual, Belén , Masdeu, Joseph C. , Tsapkini, Kyrana , Huey, Edward D. , Fisher, Daniel , Balaji, Akshata, Sah, Eric , Rascovsky, Katya, Ghoshal, Nupur , Domoto‐Reilly, Kimiko , Kornak, John , Onyike, Chiadi U. , Huang, Eric J. , Yokoyama, Jennifer S. , Paulson, Henry L. , Wong, Bonnie , Damme, Philip Van , Barmada, Sami J. , Rezaii, Neguine , Sah, Eric , Paulson, Henry L , Van Damme, Philip , Pascual, Belen , Yokoyama, Jennifer , Domoto-Reilly, Kimiko , Barmada, Sami , Morrow, Christopher , Kamath, Vidyulata , Dickerson, Bradford Clark , Lapid, Maria I. , Rojas, Julio C., Masdeu, Joseph C , Pantelyat, Alexander , Balaji, Akshata, Litvan, Irene

Mayo Clinic

Psychiatry and Clinical Neurosciences | March 13, 2025 | Volume: 79 | Issue: 6 | Pages: 327-335

10.1111/pcn.13810 | PMID 40079430 Get It

Aim Cognitive and behavioral phenomena define behavioral variant frontotemporal dementia (bvFTD), but neuropsychiatric symptoms (NPS) outside the core criteria are common throughout the illness. Identifying how NPS cluster in bvFTD may guide development of future therapies. Methods Participants ( n = 354) with sporadic and genetic bvFTD were enrolled in the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Consortium. Dementia stage was defined as early (CDR® plus NACC FTLD ≤1) or advanced (CDR® plus NACC FTLD ≥1). Baseline and annual follow‐up visit data were analyzed to compare NPS across stages of bvFTD. Psychiatric states were captured using the Neuropsychiatric Inventory‐Questionnaire and Clinician Judgment of Symptoms. Polychoric cluster analysis was used to describe NPS clusters. Results NPS were highly prevalent (≥90%) in early and late bvFTD. Four NPS clusters were identified based on magnitude of factor loadings: affective, disinhibited, compulsive, and psychosis. Neuropsychiatric symptoms fluctuated across visits. In the affective cluster, depression showed the least visit‐to‐visit stability. In the disinhibited cluster, elation showed the least stability. Symptoms in the psychosis and compulsive clusters (hallucinations, delusions, obsessions/compulsions, and hyperorality) were largely stable, persisting from visit‐to‐visit in more than 50% of cases. Symptoms in the affective and disinhibited cluster were associated with the highest caregiver burden, while symptoms in the obsessive cluster were associated with the most functional impairment. Conclusion NPS in bvFTD are frequent and cluster into four discrete groups. The fluctuating nature of some NPS in bvFTD suggests that they may not be reliable markers of disease progression or stage.
Optimizing Electroconvulsive Therapy With E-Field Modeling
Ren, Caili , Kung, Simon , Forester, Brent P. , Hermida, Adriana P., Petrides, Georgios, Seiner, Stephen J., Pagali, Sandeep R. , Yoon, Isabel A , Lapid, Maria I. , Croarkin, Paul E. , Opitz, Alexander , Mueller, Martina , Yoon, Isabel A.

Mayo Clinic

The Journal of ECT | January 24, 2025 | Volume: 41 | Issue: 4 | Pages: 281-285

10.1097/yct.0000000000001111 | PMID 39853304 Get It

Abstract Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing. This review synthesizes current knowledge on E-field modeling in ECT and explores its clinical applications. It examines the variability in E-field strengths and distributions induced by ECT and their impact on clinical outcomes. Additionally, the relationship between E-field strengths, neuroplasticity, and therapeutic efficacy is discussed. Translational studies of E-field-informed ECT are highlighted, emphasizing individualized optimal amplitude dosing and potential clinical applications. This review provides useful insights into how E-field modeling can improve the effectiveness of ECT while minimizing adverse effects, helping guide future research and clinical practice.
Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease
Kornak, John , Staffaroni, Adam M. , Cadwallader, Claire J. , Lago, Argentina Lario , Webb, Julia D, Chen, Coty , Rascovsky, Katya, Miyagawa, Toji , Ramos, Eliana Marisa , Masdeu, Joseph C. , Pressman, Peter , Rademakers, Rosa , Kremers, Walter K. , Darby, Ryan, Pascual, Belén , Ghoshal, Nupur , Mackenzie, Ian R. , Li, Jingyao , Hall, Jacob , Yutsis, Maya, Litvan, Irene , Henderson, Victor W. , Sivasankaran, Rajeev , Worringer, Katie, Domoto-Reilly, Kimiko, Snyder, Allison, Kramer, Joel H. , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L., Domoto‐Reilly, Kimiko , Damme, Philip Van , Casaletto, Kaitlin B , Masdeu, Joseph C , Pascual, Belen , Litvan, Irene , Sivasankaran, Rajeev , Boeve, Brad , Van Damme, Philip , Kremers, Walter K , Domoto-Reilly, Kimiko , Saloner, Rowan , Villeda, Saul , Paolillo, Emily W. , VandeBunte, Anna M. , Pantelyat, Alexander , Tartaglia, Maria Carmela , Bozoki, Andrea C , Younes, Kyan , Lapid, Maria I. , Hsiung, Ging‐Yuek Robin , Worringer, Katie, Loureiro, Joseph , Boeve, Bradley F. , Rojas, Julio C. , Boxer, Adam L.

Mayo Clinic

Brain Communications | January 15, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcae432 | PMID 39816189 Get It

Abstract The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate ‘pro-aging’ or ‘pro-youthful’ effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear. We examined five previously identified brain rejuvenation factors in cerebrospinal fluid of adults with autosomal dominant forms of frontotemporal dementia and sporadic Alzheimer’s disease. Our frontotemporal dementia cohort included 100 observationally followed adults carrying autosomal dominant frontotemporal dementia mutations (Mage = 49.6; 50% female; 43% C9orf72, 24% GRN, 33% MAPT) and 62 non-carriers (Mage = 52.6; 45% female) with cerebrospinal fluid analysed on Somascan, and longitudinal (Mvisits = 3 years, range 1–7 years) neuropsychological and functional assessments and plasma neurofilament light chain. Our Alzheimer’s disease cohort included 35 adults with sporadic Alzheimer’s disease (Mage = 69.4; 60% female) and 56 controls (Mage = 68.8, 50% female) who completed the same cerebrospinal fluid and clinical outcome measures cross-sectionally. Levels of C-C motif chemokine ligand 11, C-C motif chemokine ligand 2, beta-2-micorglobulin, bone gamma-carboxyglutamate protein (aka Osteocalcin) and colony stimulating factor 2 in cerebrospinal fluid were linearly combined into a composite score, with higher values reflecting ‘pro-youthful’ levels. In genetic frontotemporal dementia, higher baseline cerebrospinal fluid rejuvenation proteins predicted slower decline across cognitive, functional, and neurofilament light chain trajectories; estimates were similar across genotypes. In transdiagnostic analyses, higher cerebrospinal fluid rejuvenation proteins associated with better functional, cognitive, and neurofilament light chain outcomes in adults with sporadic Alzheimer’s disease. Proteins with pre-clinical evidence for brain rejuvenation show translational clinical relevance in adults with Alzheimer’s disease and related dementias and warrant further investigation.
Clinical performance of plasma P‐tau217 for the identification of primary Alzheimer’s disease pathology or co‐pathology in sporadic frontotemporal dementia
Ljubenkov, Peter A. , Heuer, Hilary W. , Seeley, William W., Staffaroni, Adam M. , Rajbanshi, Binita, Lago, Argentina Lario , Thijssen, Elisabeth H. , Toller, Gianina , Proctor, Nicholas K. , Forsberg, Leah K. , Brushaber, Danielle , Ramos, Eliana Marisa , Coppola, Giovanni , Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan , Grant, Ian , Huey, Edward D. , Kornak, John , Lucente, Diane , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Weıntraub, Sandra , Wong, Bonnie , Rosen, Howard J. , Boxer, Adam L. , Araujo, Igor Prufer Q C, Rojas, Julio C. , VandeVrede, Lawren , Miller, Bruce L. , Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Galasko, Douglas , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Knopman, David S. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K. , Dage, Jeffrey L. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089822 Get It

AbstractBackgroundAs new anti‐amyloid immunotherapies emerge for Alzheimer’s disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P‐tau217) for the detection of primary AD or AD co‐pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.MethodParticipants were recruited through ALLFTD, a North American multisite research consortium for the longitudinal assessment of frontotemporal lobar degeneration. After excluding cases with known FTD‐causing mutations, 573 participants with sporadic disease, mild cognitive/behavioral impairment, or healthy familial controls evaluated between 2014 and 2023 were included in this analysis (45.8% female, median age 66 years). 39 of those cases underwent neuropathological evaluation. Plasma P‐tau217 was measured with the Eli Lilly electrochemiluminescence‐based assay. P‐tau217 concentrations were compared by phenotype, disease severity, genotype, and, when available, neuropathological diagnosis with non‐parametric tests. Its diagnostic performance was tested with ROC curves. Associations between plasma P‐tau217 concentrations and clinical scales of global cognition, memory, executive function, motor function, and social cognition with linear regressions and non‐parametric tests.ResultPlasma P‐tau217 concentrations were higher in logopenic variant primary progressive aphasia (lvPPA) and amnestic dementia (AmDem), compared to participants with normal cognition or other FTD phenotypes. P‐tau217 concentrations were higher in APOE e4 carriers, compared to non‐carriers, regardless of phenotype, but were not affected by disease severity. P‐tau217 concentrations showed associations with clinical measures of global cognition, memory, and executive function, but had no associations with measures of motor function or social cognition. Plasma P‐tau217 concentrations were elevated in high and intermediate ADNC scoring, or more advanced Braak stages, even when AD was not the primary pathology.ConclusionEven when FTD is suspected, high plasma p‐tau 217 concentrations are strongly associated with underlying AD as primary pathology or contributing co‐pathology. Plasma P‐tau217 could be a tool to support the development of disease‐modifying therapies for atypical Alzheimer’s disease presentations or for FTD cases with Alzheimer’s disease co‐pathology.